WaveMan
WaveMan · Company
OSTX · Os Therapies Inc
> Search tickers & screens ⌘K
LIVE
← All companies

OSTX OS Therapies (OSTX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001795091
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
20
13F, latest reported quarter

OS Therapies insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for OS Therapies Inc in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Auerbach Shalom
SELL
2025-05-09 SECtraded 2025-05-07
82,000
$164.0K
-28.8%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Apr 10, 2025.
  • The trade is 3.1% of the 2,664,199 shares held after it.
  • No other insider sold within 30 days.
  • 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Auerbach Shalom sold about $164.0K of OSTX on May 7, 2025; 20 funds added in the latest 13F quarter.
Auerbach Shalom
SELL
2025-04-11 SECtraded 2025-04-10
10,000
$13.9K
-7.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Apr 9, 2025.
  • The trade is 0.4% of the 2,746,199 shares held after it.
  • No other insider sold within 30 days.
  • 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Auerbach Shalom sold about $13.9K of OSTX on Apr 10, 2025; 20 funds added in the latest 13F quarter.
Auerbach Shalom
SELL
2025-04-11 SECtraded 2025-04-09
50,012
$67.5K
-7.6%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jan 15, 2025.
  • The trade is 1.8% of the 2,756,199 shares held after it.
  • No other insider sold within 30 days.
  • 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Auerbach Shalom sold about $67.5K of OSTX on Apr 9, 2025; 20 funds added in the latest 13F quarter.
Einodmil LLC
SELL
2025-02-18 SECtraded 2025-02-14
100,000
$284.0K
-34.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 4.1% of the 2,431,211 shares held after it.
  • 1 other insider sold within 30 days.
  • 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Einodmil LLC sold about $284.0K of OSTX on Feb 14, 2025, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 20 funds added in the latest 13F quarter.
Auerbach Shalom
SELL
2025-01-17 SECtraded 2025-01-15
16,720
$112.7K
-61.2%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 0.7% of the 2,531,211 shares held after it.
  • 1 other insider sold within 30 days.
  • 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Auerbach Shalom sold about $112.7K of OSTX on Jan 15, 2025, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 20 funds added in the latest 13F quarter.
5 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
20 funds bought in last quarter
below 68% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
6.4% of the float short (float per yahoo 2026-10-26) · 3.9 days to cover · settled 2026-09-30
more than 54% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch OSTX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-33.1%12M
-36%-16%+4%+24%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns OSTX: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
777,651 sh
$1.5M
HOWARD FINANCIAL SERVICES, LTD.
496,002 sh
$942.4K
CM Management, LLC
400,000 sh
$760.0K
GEODE CAPITAL MANAGEMENT, LLC
301,794 sh
$573.4K
BlackRock, Inc.
242,479 sh
$460.7K

Congress trades in OSTX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

OSTX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

OSTX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$85.5K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$209.8K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$14.1K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$310.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$686.9K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$74.7K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 20 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

OSTX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$19.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-74.13x
TTM operating cash flow over current debt only, 2024-06-30 (24 months older than the period end)
Return on equity
n/a
average equity is zero or negative
Return on assets
-389.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no cash line filed
FCF yield
-34.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Operating income-$28.7M-$6.8M-$4.3M
Net income-$28.8M-$8.9M-$7.8M
EPS (diluted)-0.98-1.28-1.46
Operating cash flow-$14.2M-$7.3M-$3.0M
SEC XBRL, fiscal years, as known on 2026-10-28

OSTX Stock Sonar score 3/7 axes

Find similar shapesCompare

OSTX ranks highest on risk and compliance (52nd percentile) and institutional and government (32nd), and lowest on financial health (8th), among Pharma & Biotech peers.

Financial health
8
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-74.13x · 8 pct, sector of 371
Institutional and government
32
Inputs
  • Funds adding, latest quarter20 · 32 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
52
Inputs
  • Short interest, % of float+6.4% · 52 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Growth, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies